TSC-201 HLA-B*07:02 is under clinical development by TScan Therapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TSC-201 HLA-B*07:02’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TSC-201 HLA-B*07:02 overview
TSC-201 is under development for the treatment of anal, cervical, head and neck, non-small lung cancer, ovarian cancer and melanoma. The therapeutic candidate comprises autologous T cells engineered to express a T-cell receptor (TCR) targeting cells expressing melanoma associated antigen C2 (MAGE-C2). The drug candidate is being developed based on the TScan platform technology.
TScan Therapeutics overview
TScan Therapeutics (TScan) is a clinical-stage biotechnology company. It focuses on the development of T cell receptor (TCR) engineered T cell therapies to treat cancer. The company’s pipeline products include TSC-100 and TSC-101 for the treatment of acute myeloid leukemia and myelodysplastic syndrome; and TSC-200 to treat head and neck, cervical, and anogenital cancer. TScan is also developing various other drug candidates for the treatment of non-small cell lung, melanoma, head and neck, and ovarian cancer. The company works in collaboration with Amgen to develop therapies for Crohn’s disease. TScan is headquartered in Waltham, Massachusetts, the US.
For a complete picture of TSC-201 HLA-B*07:02’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
